Optimization of Inhalation Therapy Considering Peak Inspiratory Flow in Patients with Exacerbation of Chronic Obstructive Pulmonary Disease in Real Clinical Practice

Aim: To determine the values of peak inspiratory flow (PIP) for choosing an inhaler in patients with exacerbation of chronic obstructive pulmonary disease (COPD) and to evaluate the possibility of optimizing inhalation therapy considering PIP in real clinical practice.

Design: Open cohort controlled prospective study.

Materials and methods. 76 people were examined. Group 1 included 32 patients with COPD exacerbation, 18 of them were re-examined before discharge and completed a survey 3 months after discharge from the hospital. Group 2 consisted of 15 patients with stable COPD. Group 3 included 29 healthy individuals. PIF using various inhalers was studied using the In-Check DIALTM G16 Clement Clarke International Limited (Great Britain), fixing the level without resistance (R0) and 5 levels of resistance (R1–R5). Suboptimal PIF (sPIF) values were considered at R0 < 90, R1–R4 < 60, R5 < 30 l/min. Spirometry was performed on a Flowscreen II spirometer (Jaeger) with a flow-volume curve recording, calculation of generally accepted indicators, and on a PTS-14P-01 pressure-tachospirograph to determine the peak inspiratory rate. Statistical data processing was carried out using the Statistica v. 10. According to the Bonferroni principle, differences were considered significant at p < 0.005.

Results. During exacerbation of COPD, a decrease in PIF from 120 to 40 l/min (p < 0.001 compared with the control) and the presence of sPIF in 5–75% of cases, depending on the type of inhalation device, were revealed (no sPIF was noted in the control). Most patients were free to use a nebulizer, a metered-dose aerosol inhaler (MAI), a liquid inhaler (Respimat) and a breathhaler upon admission to the hospital. Patients could not create the necessary inspiratory effort when using the ellipt in 47% of cases, turbuhaler — in 63%, nexthaler — in 75%, handihaler — in 31%. With proven positive clinical and functional dynamics during treatment (increase in FEV1 from 37% (28; 53) to 55% (37; 62), p < 0.004), the identified changes persisted by the time of discharge from the hospital and did not reach the values of PIF and sPIF, determined in stable COPD. Analysis of PIF and sPIF in patients in real clinical practice, depending on the drugs received, showed that by the time they were discharged from the hospital, half of the patients had sPIF, continued to use turbuhaler and handihaler inhalers, and were not able to create an adequate PIF for effective inhalation of drugs. A survey of patients 3 months after discharge from the hospital showed that patients with optimal PIF values, who used drugs with the help of PPI, Respimat and Breezhaler, did not have exacerbations within the indicated periods. Patients with CPIP who continued to use the combination of turbuhaler and handihaler had moderate exacerbations. Conclusion. Optimization of inhalation therapy based on PIP in patients with COPD exacerbation should include: 1) the possibility of choosing the optimal inhaler, considering the direct determination of PIF; 2) replacement of a high-resistance powder inhaler with a PDI/ Respimat or a low-resistance powder inhaler (breather, ellipta); 3) education of COPD patients in the correct technique of inhalation. PIF testing in COPD exacerbations may help clinicians identify patients at higher risk of readmission and personalize powder inhaler selection.

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Report 2023). Available at: https://goldcopd.org/2023-gold-report-2/ [data of assess: April 24, 2023].

2. Alqahtani J.S., Aldabayan Y.S., Aldhahir A.M. et al. Predictors off 30- and 90-day COPD exacerbation readmission: a prospective cohort study. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:2769–2781. DOI: 10.2147/COPD.S328030

3. Loh C.H., Peters S.P., Lovings T.M., Ohar J.A. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann. Am. Thorac. Soc. 2017;14(8):1305–1311. DOI: 10.1513/AnnalsATS.201611-903OC

4. Leving M., Wouters H., de la Hoz A. et al. Impact of PIF, inhalation technique and medication adherence on health status and exacerbations in COPD: protocol of a real-world observational study (PIFotal COPD study). Pulm. Ther. 2021;7(2):591–606. DOI: 10.1007/s41030-021-00172-7

5. Aisanov Z.R., Arkhipov V.V., Avdeev S.N. et al. Suboptimal peak inspiratory flow rate in COPD patients: the importance of assessment in clinical practice. Expert Council Consensus. Pulmonologiya. 2020;30(6):805–811. (in Russian). DOI: 10.18093/0869-0189-2020-30-6-805-811

6. Sharma G., Mahler D.A., Mayorga V.M. et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr. Pulm. Dis. 2017;4(3):217–224. DOI: 10.15326/jcopdf.4.3.2017.0183

7. Mahler D.A., Niu X., Deering K.L., Dembek C. Prospective evaluation of exacerbations associated with suboptimal peak inspiratory flow among stable outpatients with COPD. Int. J. Chron. Obstruct Pulmon Dis. 2022;17:559–568. DOI: 10.2147/COPD.S35344

8. Harb H.S., Laz N.I., Rabea H., Abdelrahim M.E.A. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. Eur. J. Pharm. Sci. 2020;147:105298. DOI: 10.1016/j.ejps.2020.105298

9. Broeders M.E., Molema J., Hop W.C. et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir. Med. 2004;98(12):1173–1179. DOI: 10.1016/j.rmed.2004.04.010

10. Clark B., Wells B.J., Saha A.K. et al. Low peak inspiratory flow rates are common among COPD inpatients and are associated with increased healthcare resource utilization: a retrospective cohort study. Int. J. Chron. Obstruct. Pulmon. Dis. 2022;17:1483–1494. DOI: 10.2147/COPD.S355772

11. Sharova N.V., Cherkashin D.V., Sobolev A.D., Solov'ev I.A. Detection of peak inspiratory flow for a selected inhaler in patients with chronic obstructive pulmonary disease without an exacerbation. Biotechnosphere. 2022;1:28–33. (in Russian). DOI: 10.25960/bts.2022.1.28

12. Sanders M.J. Guiding inspiratory flow development of the in check DIAL G 16, a tool for improving inhaler technigue. Pulm. Med. 2017;2017:1495867. DOI: 10.1155/2017/1495867

13. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologiya. 2022;32(3):356–392. (in Russian). DOI: 10.18093/0869-0189-2022-32-3-356-392

14. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987;106(2):196–204. DOI: 10.7326/0003-4819-106-2-196

15. Kuzubova N.A., Sklyarova D.B. Comparative efficiency of using different models of nebulizers in exacerbation of chronic obstructive pulmonary disease. breast cancer. RMJ. Medical Review 2019;3(2-1):13–17. (in Russian).

16. Hua J., Zhang W., Cao H.F. et al. Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial. BMJ Open. 2020;10(5):e034804. DOI: 10.1136/bmjopen-2019-034804. Erratum in: BMJ Open. 2020;10(8):e034804corr1

17. Chikina, S.Yu. The use of different inhalers in patients with COPD: the impact of inspiratory rate and the role of learning. Atmosphere. Pulmonology and Allergology. 2008;3:46–48. (in Russian).

18. Vizel' A.A., Rezapova A.I., Vizel' I.Yu., Amirov N.B. On the search for an “ideal” means of delivering substances in obstructive respiratory diseases, an observational study in comparison with literature data. Bulletin of Modern Clinical Medicine. 2020;13(2):22–30. (in Russian). DOI: 10.20969/VSKM.2020.13(2):22-30

19. Arhipov V.V. New options for choosing an inhalation device for patients with bronchial asthma and chronic obstructive pulmonary disease. Russian Medical Journal. 2020;9:46–50. (in Russian).

20. Pavkov R., Mueller S., Fiebich K. et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr. Med. Res. Opin. 201026(11):2527–2533. DOI: 10.1185/03007995.2010.518916

21. Romanovskikh A.G., Belotserkovskaia Y.G., Smirnov I.P. Inhalation device choice for patients with broncho-obstructive disorders. Consilium Medicum. 2020;22(3):55–60. (in Russian). DOI: 10.26442/20751753.2020.3.20010

22. Chrystyn H., Safioti G., Keegstra J.R, Gopalan G. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: an in-vitro comparison of Spiromax with Turbuhaler. Int. J. Pharm. 2015;491(1–2):268–276. DOI: 10.1016/j.ijpharm.2015.05.076

23. Price D.B., Román-Rodríguez M., McQueen R.B. et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J. Allergy Clin. Immunol. Pract. 2017;5(4):1071–1081.e9. DOI: 10.1016/j.jaip.2017.01.004

24. Chen S.Y., Huang C.K., Peng H.C. et al. Peak-inspiratory-flow-rate guided inhalation therapy reduce severe exacerbation of COPD. Front. Pharmacol. 2021;12:704316. DOI: 10.3389/fphar.2021.704316